Aduro BioTech Garners $55,000,000 Series C Funding Round

  • Feed Type
  • Date
    6/12/2014
  • Company Name
    Aduro BioTech
  • Mailing Address
    626 Bancroft Way Berkeley, CA 94710 USA
  • Company Description
    Aduro BioTech is a clinical-stage immunotherapy company with a platform technology for therapeutic and prophylactic vaccines for cancer and infectious diseases. The platform of attenuated and targeted vaccines based on Listeria monocytogenes has been in development for nine years.
  • Website
    http://www.adurobiotech.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $55,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Aduro plans to use the new capital to advance its lead program in metastatic pancreatic cancer through its ongoing Phase 2b ECLIPSE clinical trial, to continue clinical development in mesothelioma and high-grade glioma, to expand into additional indications and to advance its small molecule program targeting the immunomodulatory STING receptor.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

By posting a comment, you agree to our terms and conditions.